$1.26
-0.05-3.82%
Last update: Nov 12, 8:59 AM
ProQR Therapeutics NV
PRQRNASDAQ
ProQR Therapeutics fell 41.7% from $2.16 to $1.26, behind the S&P 500's +11.2%. Its worst day was Jan 9 (−15.7%), and its low came Oct 26 at $1.24.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
ProQR Therapeutics shares fell 14.1%, while the S&P 500 rose 0.1%.
−14.1% · S&P 500 +0.1%
ProQR Therapeutics closed at its highest level of the year, 13.4% above where the year started.
+5.2% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
ProQR Therapeutics shares fell 15.7%, while the S&P 500 rose 0.7%.
−15.7%, the year's worst day · S&P 500 +0.7%
ProQR Therapeutics shares rose 13.3%, while the S&P 500 rose 0.7%.
+13.3% · S&P 500 +0.7%
EPS of $-0.09 missed the $-0.08 estimate on $5.5M revenue (est. $8.6M).
−5.0% · S&P 500 −1.5%
EPS of $-0.15 beat the $-0.15 estimate on $2.4M revenue (est. $5.5M).
−0.6% · S&P 500 −0.2%
ProQR Therapeutics shares rose 13.2%, while the S&P 500 rose 1.0%.
+13.2% · S&P 500 +1.0%
ProQR Therapeutics shares rose 19.6%, while the S&P 500 rose 1.6%.
+19.6%, the year's best day · S&P 500 +1.6%
EPS of $-0.09 beat the $-0.14 estimate on $10.2M revenue (est. $5.6M).
−0.5% · S&P 500 +0.7%
ProQR Therapeutics closed at its lowest level of the year, 42.6% below where the year started.
−3.9% · S&P 500 +0.7%
Where it ended: a close of $1.26 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.11, revenue est. $5.3M).
Nothing in the past 12 months.
All PRQR dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PRQR and SPY from Benzinga historical bars. Not investment advice.
